Efficacy and safety of alirocumab 150 mg every 4 weeks in hypercholesterolemic patients on non-statin lipid-lowering therapy or lowest strength dose of statin: ODYSSEY NIPPON

World Health Organization (WHO), 2000 Farzadfar, 2011, National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants, Lancet, 377, 578, 10.1016/S0140-6736(10)62038-7 Cholesterol Treatment Trialists (CTT) Collaboration, 2010, Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials, Lancet, 376, 1670, 10.1016/S0140-6736(10)61350-5 Matsuzawa, 2003, Sustained reduction of serum cholesterol in low-dose 6-year simvastatin treatment with minimum side effects in 51,321 Japanese hypercholesterolemic patients, Circ J, 67, 287, 10.1253/circj.67.287 Liao, 2007, Safety and efficacy of statins in Asians, Am J Cardiol, 99, 410, 10.1016/j.amjcard.2006.08.051 Chang, 2013, Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information, BMJ Open, 3, e002040, 10.1136/bmjopen-2012-002040 Arnold, 2010, Exploring differences in drug doses between Japan and Western countries, Clin Pharmacol Ther, 87, 714, 10.1038/clpt.2010.31 Teramoto, 2016, Low-density lipoprotein cholesterol levels and lipid-modifying therapy prescription patterns in the real world: an analysis of more than 33,000 high cardiovascular risk patients in Japan, Atherosclerosis, 251, 248, 10.1016/j.atherosclerosis.2016.07.001 Teramoto, 2013, Epidemiological studies of cholesterol management by statin treatment in 2012 edition of atherosclerotic cardiovascular disease prevention guidelines, Jpn Pharmacol Ther, 41, 415 Teramoto, 2012, Japan Lipid Guideline Achievement Program I. Cross-sectional survey to assess the status of lipid management in high-risk patients with dyslipidemia: clinical impact of combination therapy with ezetimibe, Curr Ther Res Clin Exp, 73, 1, 10.1016/j.curtheres.2012.02.001 Fujisue, 2017, Current status of lipid management in acute coronary syndrome, J Cardiol, 70, 101, 10.1016/j.jjcc.2017.02.004 Ogura, 2018, PCSK9 inhibition in the management of familial hypercholesterolemia, J Cardiol, 71, 1, 10.1016/j.jjcc.2017.07.002 McKenney, 2012, Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy, J Am Coll Cardiol, 59, 2344, 10.1016/j.jacc.2012.03.007 Roth, 2012, Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia, N Engl J Med, 367, 1891, 10.1056/NEJMoa1201832 Stein, 2012, Lancet, 380, 29, 10.1016/S0140-6736(12)60771-5 Roth, 2014, Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia: results of a 24 week, double-blind, randomized Phase 3 trial, Int J Cardiol, 176, 55, 10.1016/j.ijcard.2014.06.049 Bays, 2015, Alirocumab as add-on to atorvastatin versus other lipid treatment strategies: ODYSSEY OPTIONS I randomized trial, J Clin Endocrinol Metab, 100, 3140, 10.1210/jc.2015-1520 Cannon, 2015, Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial, Eur Heart J, 36, 1186, 10.1093/eurheartj/ehv028 Kastelein, 2015, ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia, Eur Heart J, 36, 2996 Kereiakes, 2015, Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study, Am Heart J, 169, 10.1016/j.ahj.2015.03.004 Robinson, 2015, Efficacy and safety of alirocumab in reducing lipids and cardiovascular events, N Engl J Med, 372, 1489, 10.1056/NEJMoa1501031 Teramoto, 2016, Efficacy and safety of alirocumab in Japanese patients with heterozygous familial hypercholesterolemia or at high cardiovascular risk with hypercholesterolemia not adequately controlled with statins – ODYSSEY JAPAN randomized controlled trial, Circ J, 80, 1980, 10.1253/circj.CJ-16-0387 Stroes, 2016, Efficacy and safety of alirocumab 150mg every 4 weeks in patients with hypercholesterolemia not on statin therapy: the ODYSSEY CHOICE II Study, J Am Heart Assoc, 5 Careskey, 2008, Atorvastatin increases human serum levels of proprotein convertase subtilisin/kexin type 9, J Lipid Res, 49, 394, 10.1194/jlr.M700437-JLR200 Rey, 2016, Relationship between low-density lipoprotein cholesterol, free proprotein convertase subtilisin/kexin type 9, and alirocumab levels after different lipid-lowering strategies, J Am Heart Assoc, 5, 10, 10.1161/JAHA.116.003323 Teramoto, 2017, Efficacy and safety of alirocumab in patients with hypercholesterolemia not adequately controlled with non-statin lipid-lowering therapy or the lowest strength of statin: ODYSSEY NIPPON study design and rationale, Lipids Health Dis, 16, 121, 10.1186/s12944-017-0513-7 Teramoto, 2013, Comprehensive risk management for the prevention of cardiovascular disease: executive summary of the Japan Atherosclerosis Society (JAS) guidelines for the diagnosis and prevention of atherosclerotic cardiovascular diseases in Japan – 2012, J Atheroscler Thromb, 20, 603, 10.5551/jat.15867 Scientific Steering Committee on behalf of the Simon Broome Register Group, 1991, Risk of fatal coronary heart disease in familial hypercholesterolaemia, BMJ, 303, 893, 10.1136/bmj.303.6807.893 World Health Organization. Familial Hypercholesterolemia (FH). Report of a second WHO Consultation; 1998. http://whqlibdoc.who.int/hq/1999/WHO_HGN_FH_CONS_99.2.pdf?ua=1. [Accessed 14 June 2018]. Sharrett, 2001, Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) Study, Circulation, 104, 1108, 10.1161/hc3501.095214 Tada, 2017, Lipid management in a Japanese community:attainment rate of target set by the Japan Atherosclerosis Society Guidelines for the Prevention of Atherosclerotic Cardiovascular Diseases 2012, J Atheroscler Thromb, 24, 338, 10.5551/jat.36004 Gaudet, 2014, Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150mg every two weeks dosing from phase 2 trials), Am J Cardiol, 114, 711, 10.1016/j.amjcard.2014.05.060 Tan, 2003, Do Singapore patients require lower doses of statins? The SGH Lipid Clinic experience, Singap Med J, 44, 635 Morales, 2004, Efficacy and safety of simvastatin in Asian and non-Asian coronary heart disease patients: a comparison of the GOALLS and STATT studies, Curr Med Res Opin, 20, 1235, 10.1185/030079904125004367 Birmingham, 2015, Rosuvastatin pharmacokinetics and pharmacogenetics in Caucasian and Asian subjects residing in the United States, Eur J Clin Pharmacol, 71, 329, 10.1007/s00228-014-1800-0 Stroes, 2015, Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment Aetiology and Management, Eur Heart J, 36, 1012, 10.1093/eurheartj/ehv043 Bruckert, 2005, Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients – the PRIMO study, Cardiovasc Drugs Ther, 19, 403, 10.1007/s10557-005-5686-z Mancini, 2011, Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference, Can J Cardiol, 27, 635, 10.1016/j.cjca.2011.05.007 Rosenson, 2014, The National Lipid Association's Muscle Safety Expert Panel. An assessment by the Statin Muscle Safety Task Force: 2014 update, J Clin Lipidol, 8, S58, 10.1016/j.jacl.2014.03.004